SCHEMBL4560200

SCHEMBL4560200

NC(=O)c1cnc(N)nc1-c1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 6/20 0.56
ADORA1 P30542 9/20 0.54
ADORA2A P29274 6/20 0.54
LMNA P02545 1/20 0.48
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
PARP1 P09874 1/20 0.47
IKBKB O14920 1/20 0.46
CCNT1 O60563 1/20 0.46
JAK2 O60674 1/20 0.46
CCNB2 O95067 1/20 0.46
CCNE2 O96020 1/20 0.46
PRKCB P05771 1/20 0.46
CDK1 P06493 1/20 0.46
CCNB1 P14635 1/20 0.46
CCNA2 P20248 1/20 0.46
CCNE1 P24864 1/20 0.46
CDK2 P24941 1/20 0.46
GSK3B P49841 1/20 0.46
CDK9 P50750 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30315868 0.88 ADORA1 (0.55) CDC7ADORA1ADORA2ALMNAMEN1
SCHEMBL18351966 0.83 ADORA1 (0.51) CDC7ADORA1ADORA2ALMNAKMT2A
SCHEMBL13723345 0.82 ADORA1 (0.57) CDC7ADORA1PARP1
SCHEMBL28927188 0.81 ALDH1A1 (0.52) ADORA1ADORA2ALMNAMEN1KMT2A
SCHEMBL17610492 0.81 IKBKB (0.49) CDC7ADORA1ADORA2APARP1IKBKB
SCHEMBL13723824 0.79 PARP1 (0.49) CDC7ADORA1LMNAPARP1CDK2
SCHEMBL13723740 0.79 ADORA2A (0.60) CDC7ADORA1ADORA2APARP1IKBKB
SCHEMBL1651798 0.78 PLAU (0.45) CDC7ADORA1ADORA2AIKBKBCCNT1
SCHEMBL16465327 0.78 CDC7 (0.52) CDC7ADORA1ADORA2APARP1JAK2
SCHEMBL14320333 0.78 NNMT (0.43) CDC7ADORA1ADORA2APARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1648464-A1 2-AMINO-4-HYDROXY-5-PYRIMIDINCARBOXAMID DERIVATIVES AND RELATED COMPOUNDS AS T-CELL ACTIVATION INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS AMGEN INC. (US) 2006-04-26 EP claimed
WO-2005009443-A1 2-AMINO-4-HYDROXY-5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF T CELL ACTIVATION FOR THE TREATMENT OF INFLAMMATORY DISEASES AMGEN INC. (US) 2005-02-03 WO claimed
US-7504396-B2 Substituted heterocyclic compounds and methods of use AMGEN INC. (US) 2009-03-17 US disclosed
EP-1648464-A1 2-AMINO-4-HYDROXY-5-PYRIMIDINCARBOXAMID DERIVATIVES AND RELATED COMPOUNDS AS T-CELL ACTIVATION INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS AMGEN INC. (US) 2006-04-26 EP disclosed
US-20050209221-A1 Substituted heterocyclic compounds and methods of use AMGEN INC. 2005-09-22 US disclosed
WO-2005009443-A1 2-AMINO-4-HYDROXY-5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF T CELL ACTIVATION FOR THE TREATMENT OF INFLAMMATORY DISEASES AMGEN INC. (US) 2005-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050209221-A1 Substituted heterocyclic compounds and methods of use ICOS, CD4, HLA-DRB1 CDC7 1393/4885ADORA1 1326/4885ADORA2A 1722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.